{"id":2952,"date":"2026-09-07T19:14:00","date_gmt":"2026-09-07T23:14:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2952"},"modified":"2026-09-08T20:40:13","modified_gmt":"2026-09-09T00:40:13","slug":"cebpa-model-recreates-rtk-ras-leukemic-evolution","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2952","title":{"rendered":"CEBPA Model Recreates RTK\u2013RAS Leukemic Evolution"},"content":{"rendered":"

Evidence<\/strong> Rolling-window publication catch-up · Peer-Reviewed<\/strong> September 4, 2026 · Discovery<\/strong> September 7, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Uncertain<\/p>\n

\"CEBPA<\/p>\n

Summary<\/h4>\n

University of Cambridge and Wellcome Sanger Institute researchers reported an immunocompetent, stepwise model of myeloid-neoplasm evolution. A patient-derived CEBPA N321D mutation created a long-lived premalignant state in Hoxb8-FL murine progenitors; every primary recipient developed fatal leukemia after prolonged latency, and every sequenced tumor acquired a secondary RTK–RAS-pathway mutation. The model offers unusually accessible premalignant, transformation and overt-disease stages, but it does not establish a human biomarker, drug response or therapeutic target. Its strongest value is experimental: testing mutation order, resistance and immune-context dependencies under endogenous RTK–RAS regulation.<\/p>\n

What Happened<\/h4>\n

CEBPA N321D permitted Hox-independent propagation and produced a self-renewing plasmacytoid-dendritic-progenitor-like state in vitro. After transplantation, all 12 mutant-cell recipients developed leukemia; untreated recipients had a median survival of 257 days, while an additional low-dose irradiation cohort developed disease at roughly 190 days. Control cells disappeared after seven days and did not produce leukemia.<\/p>\n

Whole-exome sequencing found RTK–RAS alterations in all 14 tumors analyzed across the primary and pilot experiments, involving Ptpn11, Cbl, Flt3, Kras or Nras. Several variants matched recurrent patient mutations, including KRAS G12D and G13D, NRAS G12V and Q61H, and high variant-allele fractions placed the signaling events among dominant late drivers. Secondary transplantation from two primary tumors produced disease within 18–42 days. Single-cell profiling showed multilineage premalignant output but lineage-restricted overt tumors; seven of 21 tumors had mixed or lymphoid-biased phenotypes.<\/p>\n

Deep Analysis<\/h4>\n

A tractable evolution and resistance platform:<\/strong> The deterministic selection of five RTK–RAS genes after a defined transcription-factor lesion supports a reproducible system for interrogating cooperative mutation order. Because mutations arise in endogenous loci and tumors propagate in immunocompetent mice, the platform may enable pharmacology and resistance experiments that conventional overexpression or immunodeficient xenograft systems cannot. The counterargument is that reproducibility may partly reflect the engineered starting cell, retroviral CEBPA expression, Flt3L-conditioned culture and transplantation environment rather than a universal rule of human leukemogenesis.<\/p>\n

A disease-specific model with limited direct generalizability:<\/strong> The pDC-like premalignant state, retained differentiation and RAS-pathway convergence resemble selected features of juvenile myelomonocytic leukemia and CEBPA-mutant AML. Yet the authors explicitly state that this is not a direct JMML model: CEBPA is the initiating lesion, RTK–RAS mutations arise late, and some tumors produce B-lineage output. Small cohorts, lethal irradiation, murine cells and absence of patient-derived validation constrain disease attribution and treatment prediction.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: peer-reviewed version of record published September 4; 12 of 12 primary mutant recipients developed leukemia; 14 of 14 sequenced tumors carried RTK–RAS-pathway mutations; endogenous secondary mutations included patient-observed amino-acid substitutions; tumor cells engrafted in secondary hosts; the model is immunocompetent and data are publicly deposited. Missing facts: prospective prediction of mutation choice, validation in human CEBPA-mutant premalignancy, drug-response benchmarking, clonal-bottleneck analysis, pharmacokinetics, toxicity and licensing or spinout status. Upgrade evidence would be cross-laboratory replication, concordance with longitudinal patient clones and correct prediction of response or resistance to genotype-matched therapy. Downgrade evidence would be mutation convergence driven by culture, irradiation or transplantation artifacts.<\/p>\n

Company and Product Background<\/h4>\n

The work was led by the Cambridge Stem Cell Institute and Department of Haematology at the University of Cambridge, with whole-exome sequencing support from the Wellcome Sanger Institute. No company product, licensing transaction or patent position was disclosed. One author is now employed by AstraZeneca, but the paper states that the work was performed during prior academic employment; no strategic inference follows from that affiliation.<\/p>\n

CEBPA encodes a transcription factor central to myeloid differentiation. C-terminal bZIP mutations define a recognized AML subgroup and can act early in leukemic evolution. The modeled N321D lesion generated self-renewal without immediate overt disease. Subsequent mutations in FLT3, RAS, PTPN11 or CBL activate growth and survival signaling, providing the second step. The platform could be used to test pathway inhibitors, combinations and resistance evolution, but no therapeutic experiment was reported.<\/p>\n

InSilens Take<\/h4>\n

The signal is the experimental architecture, not a new treatment. A long-latency premalignant phase that repeatedly converges on endogenous, patient-relevant RTK–RAS lesions creates a potentially useful bridge between retrospective human genomics and prospective intervention studies. The strongest alternative explanation is system-specific selection imposed by Hoxb8-FL cells, Flt3L culture and irradiated transplantation. Until the model predicts human clonal behavior or therapy response, it should be treated as a high-value discovery tool rather than a validated preclinical surrogate.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — a reproducible hematologic-malignancy model spanning premalignancy through overt leukemia with consistent pathway-level evolution<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nUncertain — mechanistically coherent and enabling, but no therapeutic validation or human predictive evidence yet<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — peer reviewed, open access, with disclosed in-vivo, sequencing and single-cell methods<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — translational utility depends on reproducibility, patient concordance and predictive pharmacology<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

University of Cambridge and Wellcome Sanger Institute researchers reported an immunocompetent, stepwise model of myeloid-neoplasm evolution. A patient-derived CEBPA N321D mutation created a long-lived premalignant state in Hoxb8-FL murine progenitors; every primary recipient developed…<\/p>\n","protected":false},"author":1,"featured_media":2983,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[586,588,587,584,585],"class_list":["post-2952","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-cebpa","tag-myeloid-neoplasm","tag-rtk-ras-pathway","tag-university-of-cambridge","tag-wellcome-sanger-institute"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2952"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2952\/revisions"}],"predecessor-version":[{"id":2984,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2952\/revisions\/2984"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2983"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}